Skip to main content
SpringerLink
Log in

Treatment of pancreatic cancer

Promises and problems of tamoxifen, somatostatin analogs, and gemcitabine

  • State-of-the-Art
  • Published:
International journal of pancreatology Aims and scope Submit manuscript

Summary

The clinical problem posed by pancreatic cancer is introduced, and the epidemiology and pathology of the disease are briefly presented. The natural history of this tumor is then described in order to highlight the deficiencies of current therapeutic modalities. The extremely poor results of the drug trials are reviewed, followed by a detailed discussion and critique of the trials of novel treatments that include gemcitabine, somatostatin analogs, and tamoxifen. Finally, areas for future development are indicated.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Evans DB, Abbruzzese JL, Rich TR. Cancer of the pancreas, inCancer: Principles and Practice of Oncology, Devita VT, Hellman S, Rosenberg SA, eds. Lippincott, Philadelphia, 1997, pp. 1054–1087.

    Google Scholar 

  2. Wingo PA, Tong T, Bolden S. Cancer statistic 1995.CA 1995; 45: 8–30.

    PubMed  CAS  Google Scholar 

  3. Gudjonsson B. Cancer of the pancreas.Cancer 1987; 60: 2284–2303.

    PubMed  CAS  Google Scholar 

  4. Tsuchiya R, Noda T, Harada N, Miyamoto T, Tomioka T, Yamamoto K, et al. Collective review of small carcinomas of the pancreas.Ann Surg 1986; 203: 77–81.

    PubMed  CAS  Google Scholar 

  5. Friess H, Buchler M, Beglinger C, Weber A, Kunz J, Fritsch K, et al. Low-dose octreotide treatment is not effective in patients with advanced pancreatic cancer.Pancreas 1993; 8: 540–545.

    PubMed  CAS  Google Scholar 

  6. Kelly DM, Benjamin IS. Pancreatic carcinoma.Ann Oncol 1995; 6: 19–28.

    PubMed  CAS  Google Scholar 

  7. Williamson RCN. Pancreatic cancer: the, greatest oncologic challenge.Br Med J 1988; 296: 445,446.

    Article  CAS  Google Scholar 

  8. Gordis L, Gold EB. Epidemiology of pancreatic cancer.World J Surg 1984; 8: 808–821.

    PubMed  CAS  Google Scholar 

  9. Douglass H. Adjuvant therapy for pancreatic cancer.World J Surg 1995; 19: 170–174.

    Google Scholar 

  10. American Cancer Society Cancer Facts and Figures—1991. American Cancer Society, 1991.

  11. Connolly M, Dawson P, Michelassi F, et al. Survival in 1001 patients with carcinoma of the pancreas.Ann Surg 1987; 206: 366–373.

    PubMed  CAS  Google Scholar 

  12. Singh S, Longmire W, Reber H. Surgical palliation for pancreatic cancer: the UCLA experience.Ann Surg 1990; 212: 132–139.

    PubMed  CAS  Google Scholar 

  13. Ries LAG, Miller BA, Hankey BF, et al., eds.SEER Cancer Statistics Review, 1973–1991: Tables and Graphs, National Cancer Institute, IH pub. No. 94-2789. Bethesda, MD, 1994, 356–368.

  14. Blackstock AW, Cox AD, Tepper JE. Treatment of pancreatic cancer: current limitations, future possibilities.Oncology 1996; 10: 301–303.

    PubMed  CAS  Google Scholar 

  15. Flanders TY, Foulkes WD. Pancreatic adenocarcinoma: epidemiology and genetics.J Med Genet 1996; 33: 889–898.

    PubMed  CAS  Google Scholar 

  16. Abruzzese JL.Pancreatic cancer: Overviews of current and future therapeutic approaches. Educational Book of the American Society of Clinical Oncology, 33rd Annual Meeting, Denver, CO, May 17–20, 1997; pp 65–70.

  17. Rivenson A, Hoffman D, Prokopczyk B, et al. Induction of lung and exocrine pancreatic tumors in F344 rats by tobacco-specific andAreca-derived N-nitrosamines.Cancer Res 1988; 48: 6912–6917.

    PubMed  CAS  Google Scholar 

  18. Pour PM, Rivenson A. Induction of a mixed ductal-squamous-islet cell carcinoma in a rat treated with a tobacco-specific carcinogen.Am J Pathol 1989: 134: 627–631.

    PubMed  CAS  Google Scholar 

  19. Hoffman D, Rivenson A, Chung FL, et al. Nicotine-derived N-nitrosamines (TSNA) and their relevance in tobacco carcinogenesis.Crit Rev Toxicol 1991; 21: 305–311.

    Google Scholar 

  20. Ogawa T, Makino T, Mizumoto K, et al. Promoting effect of truncal vagotomy on pancreatic carcinogenesis initiated with N-nitrosobis-(2-oxopropyl) amine in Syrian golden hamsters.Carcinogenesis 1991; 12: 1227–1230.

    PubMed  CAS  Google Scholar 

  21. Corra S, Kazakoff K, Lawson TA, et al. Cholecystokinin inhibits DNA alkylation induced by N-nitrosobis (2-oxopropyl) amine (BOP) in hamster pancreas.Cancer Lett 1992; 62: 251–256.

    PubMed  CAS  Google Scholar 

  22. Hoffman D, Rivenson A, Abbi R, et al. A study of tobacco carcinogenesis: effect of the fat content of the diet on the carcinogenic activity of 4 (methylnitros-amino)-1-(3-pyridyl)-1-butanone in F344 rats.Cancer Res 1993; 53: 2758–2761.

    Google Scholar 

  23. Rosenberg L, Brown RA, Duguid WP. Development of experimental cancer in the head of the pancreas by surgical induction of tissue injury.Am J Surg 1984; 147: 146–151.

    PubMed  CAS  Google Scholar 

  24. Silverman DT, Dunn JA, Hoover RN, et al. Cigarette smoking and pancreas cancer: a case-control study based on direct interviews.J Natl Cancer Inst 1994; 86: 1510–1516.

    PubMed  CAS  Google Scholar 

  25. La Vecchia C, Boyle P, Francesschi S, et al. Smoking and cancer with emphasis on Europe.Eur J Cancer 1991; 27: 94–104.

    Article  PubMed  Google Scholar 

  26. Yeo C, Cameron J, Lillemoe K, et al. Pancreaticoduodenectomy for cancer of the head of the pancreas.Ann Surg 1995; 221: 721–733.

    PubMed  CAS  Google Scholar 

  27. Rothenberg ML. New developments in chemotherapy for patients with advanced pancreatic cancer.Oncology 1996; 10: 18–22.

    PubMed  CAS  Google Scholar 

  28. Rothenberg ML, Abbruzzese JL, Moore M, Portenoy RK, Robertson JM, Wanebo HJ. A rationale for expanding the endpoints for clinical trials in advanced pancreatic carcinoma.Cancer 1996; 78(3 Suppl): 627–632.

    PubMed  CAS  Google Scholar 

  29. Andersen JR, Friss-Mollek A, Hancke S, et al. A controlled trial of combination chemotherapy with 5-FU and BCNU in pancreatic adenocarcinoma.Scand J Gastroenterol 1981; 16: 973.

    Article  PubMed  CAS  Google Scholar 

  30. Frey C, Twomey P, Keehn R, et al. Randomized study of 5-FU and CCNU in pancreatic cancer: report of the Veteran Administration Surgical Adjuvan Cancer Chemotherapy Study Group.Cancer 1981; 47: 27–32.

    PubMed  CAS  Google Scholar 

  31. Mallinson CN, Rake MO, Cocking JB, et al. Chemotherapy in pancreatic cancer: results of a controlled, prospective, randomised, multcentre trial.Br Med J 1980; 281: 1589–1591.

    PubMed  CAS  Google Scholar 

  32. Cullinan S, Moertel CG, Wieand HS, et al. A phase III trial on the therapy of advanced pancreatic cancer: evaluations of the Mallinson regimen and combined 5-fluorouracil, doxorubicin, and cisplatin.Cancer 1990; 65: 2207–2212.

    PubMed  CAS  Google Scholar 

  33. Kelsen D. The use of chemotherapy in the treatment of advanced gastric and pancreatic cancer.Semin Oncol 1994; 21: 58–66.

    PubMed  CAS  Google Scholar 

  34. Bukowski RM. Role of chemotherapy in patients with adenocarcinoma of the pancreas.Adv Oncol 1995; 11: 25.

    Google Scholar 

  35. Carter SK. The integration of chemotherapy into a combined modality approach for cancer treatment. VI. Pancreatic adenocarcinoma.Cancer Treat Rev 1975; 3: 193.

    Google Scholar 

  36. Hubbard KP, Pazdur R, Ajani JA, et al. Phase II evaluation of iproplatin in patients with advanced gastric and pancreatic cancer.Am J Clin Oncol 1992; 15: 524–527.

    PubMed  CAS  Google Scholar 

  37. Carlson RW, Doroshow JH, Odujinrin OO, et al. Trimetrexate in locally advanced or metastatic adenocarcinoma of the pancreas: a phase II study of the Northern California Oncology Group.Invest New Drugs 1990; 8: 387–389.

    PubMed  CAS  Google Scholar 

  38. Casper ES, Schwartz GK, Johnson B, et al. Phase II trial of edatrexate in patients with advanced pancreatic cancer.Invest New Drugs 1992; 10: 313–316.

    PubMed  CAS  Google Scholar 

  39. Casper ES, Schwartz GK, Kelsen DP. Phase II trial of fazarabine (arabinofuranosyl-5-azacytidine) in patients with advanced pancreatic adenocarcinoma.Invest New Drugs 1992; 10: 205–209.

    PubMed  CAS  Google Scholar 

  40. Bukowski RM, Fleming TR, MacDonald JS, et al. Evaluation of combination chemotherapy and phase II agents in pancreatic adenocarcinoma: a Southwest Oncology Group study.Cancer 1993; 71: 322–325.

    PubMed  CAS  Google Scholar 

  41. Linke K, Pazdur R, Abbruzzese J, et al. Phase II study of amonafide in advanced pancreatic adenocarcinoma.Invest New Drugs 1991; 9: 353–356.

    PubMed  CAS  Google Scholar 

  42. Hertel LW, Boder GB, Kroin JS, et al. Evaluation of the antitumor activity of gemcitabine (2′, 2′-difluoro-2′-deoxycytidine).Cancer Res 1990; 50: 4417–4422.

    PubMed  CAS  Google Scholar 

  43. Heinemann V, Hertel LW, Grindley GB, et al. Comparison of the cellular pharmacokinetics and toxicity of 2′, 2′-difluoro-2′-deoxycytidine and 1-β-D arabinofuranosyl-cytosine.Cancer 1988; 48: 4024–4031.

    CAS  Google Scholar 

  44. Abbruzzese JL, Grunewald R, Weeks EA, et al. A phase I clinical, plasma and cellular pharmacology study of gemcitabine.J Clin Oncol 1991; 9: 491–498.

    PubMed  CAS  Google Scholar 

  45. Casper ES, Green MR, Kelsen DP, et al. Phase II trial of gemcitabine (2′, 2′-difluoro-2′-deoxycytidine) in patients with adenocarcinoma of the pancreas.Invest New Drugs 1994; 12: 29–34.

    PubMed  CAS  Google Scholar 

  46. Andersen JS, Burris HA, Casper E, et al. Development of a new system for assessing clinical benefit for patients with advanced pancreatic cancer.Am Soc Clin Oncol 1994; 13: A1600.

    Google Scholar 

  47. Burris III HA, Moore MJ, Andersen J, et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial.J Clin Oncol 1997; 15: 2403–2413.

    PubMed  CAS  Google Scholar 

  48. Rothenberg ML, Moore MJ, Cripps MC, et al. A phase II trial of gemcitabine in patients with 5-FU-refractory pancreas cancer.Ann Oncol 1996; 7: 347–353.

    PubMed  CAS  Google Scholar 

  49. Gelber RD. Gemcitabine for pancreatic cancer: how hard to look for clinical benefit? An America perspective.Ann Oncol 1996; 7: 335–337.

    PubMed  CAS  Google Scholar 

  50. Burris III HA, Moore MJ, Andersen J, et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial.J Clin Oncol 1997; 15: 2403–2413.

    PubMed  CAS  Google Scholar 

  51. Abbruzzese JL, Levin B, Ajani JA, et al. A phase I trial of recominant human interferon-gamma and recombinant human tumor necrosis factor in patients with gastrointestinal cancer.Cancer Res 1989; 49: 4057–4061.

    PubMed  CAS  Google Scholar 

  52. Abbruzzese JL, Levin B, Ajani JA, et al. A pilot phase II trial of recombinant human interferon-gamma and recombinant human tumor necrosis factor in patients with gastrointestinal malignancies: results of a trial terminated by excessive toxicity.J Biol Response Modif 1992; 9: 522–527

    Google Scholar 

  53. Andren-Sandberg A, Borg S, Dawiskiba I, Ferno M, Estrogen receptors and estrogen binding protein in pancreatic cancer.Digestion 1982; 25: 12.

    Google Scholar 

  54. Berz C, Hollander C, Miller. Endocrine responsive pancreatic carcinoma steroid binding and cytotoxicity studies in human tumor cell lines.Cancer Res 1986; 46: 2276–2281.

    Google Scholar 

  55. Greenway B, Iqbal MJ, Johnson PJ, Williams R. Oestrogen receptor proteins in malignant and fetal pancreas.Br Med J 1981; 283: 751–753.

    CAS  Google Scholar 

  56. Satake K, Yoshimoto T, Mukai R, Umeyama K. Estrogen receptors in 7,12-dimethylbenz (a) anthracene (DMBA) induced pancreatic carcinoma in rats and in human pancreatic carcinoma.Clin Oncol 1982; 8: 49–54.

    PubMed  CAS  Google Scholar 

  57. Sandberg AA, Rosenthal HE. Steroid receptors in exocrine glands: the pancreas and prostate.J Steroid Biochem 1979; 11: 293–299.

    PubMed  CAS  Google Scholar 

  58. Pousette A, Carlstrom K, Skoldefors H, Wilking N, Thieve NO. Purification and partial characterization of a 17β-estradiol-binding macromolecule in the human pancreas.Cancer Res 1982; 42: 633–637.

    PubMed  CAS  Google Scholar 

  59. Morita S, Motohara T, Ogawa K, et al. Hormone therapy using tamoxifen in unresectable carcinoma of the pancreas— preliminary study.Nippon Igaku Hoshasen Gakkai Zasshi 1992; 52: 1686–1688.

    PubMed  CAS  Google Scholar 

  60. Thieve NO, Pousette A, Carlstrom K. Adenocarcinoma of the pancreas — a hormone sensitive tumor? A preliminary report on Novadex treatment.Clin Oncol 1983; 9: 193–197.

    Google Scholar 

  61. Tonnesen K, Kamp-Jensen M. Antiestrogen therapy in pancreatic carcinoma: a preliminary report.Eur J Surg Oncol 1986; 12: 69, 70.

    PubMed  CAS  Google Scholar 

  62. Wong A, Chan A. Survival benefit of tamifen therapy in adenocarcinoma of pancreas.Cancer 1993; 71: 2200–2203.

    PubMed  CAS  Google Scholar 

  63. Bakkevold KE, Pettersen A, Arnesjo B, et al. Tamoxifen therapy in unresectable adenocarcinoma of the pancreas and the papilla of vater.Br J Surg 1990; 77: 725–730.

    PubMed  CAS  Google Scholar 

  64. Crowson MC, Dorrell A, Rolfe EB, Fielding WL. A phase II study to evaluate tamoxifen in pancreatic adenocarcinoma.Eur J Surg Oncol 1986; 12: 335, 336.

    PubMed  CAS  Google Scholar 

  65. Taylor OM, Benson EA, McMahon MJ, et al. Clinical trial of tamoxifen in patients with irresectable pancreatic adenocarcinoma: the Yorkshire Gastrointestinal Tumor Group.Br J Surg 1993; 80: 384–386.

    PubMed  CAS  Google Scholar 

  66. Rosenberg L, Barkun A, Denis M, et al. Low dose octreotide and tamoxifen in the treatment of adenocarcinoma of the pancreas.Cancer 1995; 75: 23–28.

    PubMed  CAS  Google Scholar 

  67. Costanzi J, Chun H, Mittelman A, et al. Phase I/II clinical trial of onconase (ONC) plus tamoxifen (TMX) in patients (pts) with advanced pancreatic carcinoma (APC).Proc Am Soc Clin Oncol 1994; 13: A608.

    Google Scholar 

  68. Horimi T, Takasaki M, Toki A, Nishimura W, Morita S. The beneficial effect of tamoxifen therapy in patients with resected adenocarcinoma of the pancreas.Hepatogastroenterology 1996; 43: 1225–1229.

    PubMed  CAS  Google Scholar 

  69. Couldwell WT, Hinton DR, He S, et al. Protein kinase C inhibitors induce apoptosis in human malignant glima cell lines.FEBS Lett 1994; 345: 43–46.

    PubMed  CAS  Google Scholar 

  70. Kang Y, Cortina R, Perry RP, Role of c-myc in tamoxifen-induced apoptosis in estrogen-independent breast cancer cells.J Natl Cancer Inst 1996; 88; 279–284.

    PubMed  CAS  Google Scholar 

  71. Perry RR, Kang Y, Greaves B. Effect of tamoxifen on growth and apoptosis of estrogen-dependent and-independent human breast cancer cells.Ann Surg Oncol 1995; 2: 238–245.

    PubMed  CAS  Google Scholar 

  72. Pollack IF, Randall MS, Kristofik MP, et al. Effect of tamoxifen on DNA synthesis and proliferation of human malignant glioma cell lines in vitro.Cancer Res 1990; 50: 7134–7138.

    PubMed  CAS  Google Scholar 

  73. Toms SA, Casey G, Herchergs A, et al. Tamoxifen-induced p53 independent apoptosis in a human glioblastoma cell line.Proc Am Assoc Cancer Res 1995; 36: A47.

    Google Scholar 

  74. Vertosick FT, Selker RG, Randall MS, et al. A comparison of the relative chemosensitivity of human gliomas to tamoxifen and n-desmethyltamoxifen in vitro.J Neurooncol 1994; 19: 97–103.

    PubMed  Google Scholar 

  75. Klijn JG, Hoff AM, Planting AS, Verweij J, Kok T, Lamberts SW, et al. Treatment of patients with metastatic pancreatic and gastrointestinal tumors with the somatostatin analogue Sandostatin: a phase II study including endocrine effects.Br J Cancer 1990; 62: 627–630.

    PubMed  CAS  Google Scholar 

  76. Fekete M, Zalatnai A, Comura-Schally AM, Schally AV. Membrane receptors for peptides in experimental and human pancreatic cancers.Pancreas 1989; 4: 521–528.

    PubMed  CAS  Google Scholar 

  77. Pinski J, Milovanovic S, Yano T, Hamaoui A, Radulovic S, Cai R-Z, et al. Biological activity and receptor binding characteristics of various human tumors of acetylated somatostatin analogs.Proc. Soc Exp Biol Med 1992; 200: 49–56.

    PubMed  CAS  Google Scholar 

  78. Reubi JC, Horisberger U, Essed CE, Jeekel J, Klijn, JGH, Lamberts SWJ. Absence of somatostatin receptors in human exocrine pancreatic adenocarcinomas.Gastroenterology 1988; 95: 760–763.

    PubMed  CAS  Google Scholar 

  79. Patel YC, Greenwood MT, Warszynska A, Panetta R, Srikant CB. All five cloned human somatostatin receptors (hssTR1-5) are functionally coupled to adenyl cyclase.Biochem Biophys Res Commun 1994; 198: 605–612.

    PubMed  CAS  Google Scholar 

  80. Hofland LJ, van Koetsveld PM, Waaijers M, Zuyderwijk J, Lamberts SW. Relative potencies of the somatostatin analogs octreotide, BIM-23014, and RC-160 on the inhibition of hormone release by cultured human endocrine tumor cells and normal rat anterior pituitary cells.Endocrinology 1994; 134: 301–306.

    PubMed  CAS  Google Scholar 

  81. Johnson LR. Effects of gastrointestinal hormones on pancreatic growth.Cancer 1981; 47: 1640–1645.

    PubMed  CAS  Google Scholar 

  82. Comaru-Schally M, Schally AV. LH-RH agonists as adjuncts to somatostatin analogs in the treatment of pancreatic cancer, inInternational Symposium on Gn-RH Analogues in Cancer and Human Reproduction, Lunefield B, Vickery B, eds. Kluwer, Boston, MA, 1990; pp. 203–210.

    Google Scholar 

  83. Konturek SJ, Bilski J, Jaworek J, Tasler J, Schally AV. Comparison of somatostatin and its highly potenthexa-and octapeptide analogs on exocrine and endocrine pancreatic secretion.Proc Soc Exp Biol Med 1988; 187; 241–249.

    PubMed  CAS  Google Scholar 

  84. Stoscheck CM, King LE Jr. Role of epidermal growth factor in carcinogenesis.Cancer Res 1986; 46: 1030–1037.

    PubMed  CAS  Google Scholar 

  85. Goustin AS, Leof EB, Shipley GS, Moses HL. Growth factors and cancer.Cancer Res 1986; 46; 1015–1029.

    PubMed  CAS  Google Scholar 

  86. Korc M, Magnum BE. Recycling of epidermal growth factor in a human pancreatic carcinoma cell line.Proc Natl Acad Sci USA 1985; 82: 6172–6175.

    PubMed  CAS  Google Scholar 

  87. Lamberts SWJ, Koper JW, Reubi JC. Potential role of somatostatin analogues in the treatment of cancer.Eur J Clin Invest 1987; 17: 281–287.

    PubMed  CAS  Google Scholar 

  88. Pollak M, Constantino J, Polychronakos C, Blauer S, Guyda H, Redmond C, Fisher B, Margolese R. Effect of tamoxifen on serum insulinlike growth factor I levels in stage 1 breast cancer patients.J Natl Cancer Inst 1990; 82: 1693–1697.

    PubMed  CAS  Google Scholar 

  89. Pollak M, Polychronakos C, Guyda H. Somatostatin analogue SMS 201–995 reduces serum IGF levels in patients with neoplasms potentially dependent on IGF-1.Anticancer Res 1989; 9: 889–891.

    PubMed  CAS  Google Scholar 

  90. Huynh H, Pollak M. enhancement of tamoxifen-induced suppression of insulin-like growth factor I gene expression and serum level by a somatostatin analogue.Biochem Biophys Res Commun 1994; 203(1): 253–259.

    PubMed  CAS  Google Scholar 

  91. Poston GJ, Townsend CM Jr, Rajaraman S, Thompson JC, Singh P. Effect of somatostatin and tamoxifen on the growth of human pancreatic cancers in nude mice.Pancreas 1990; 5: 151–157.

    PubMed  CAS  Google Scholar 

  92. Morisset J, Genik P, Lord A, Solomon TE. Effects of chronic administration of somatostatin on rat exocrine pancrreas.Regul Pept 1982; 4: 49–58.

    PubMed  CAS  Google Scholar 

  93. Upp JR Jr, Olson D, Poston GJ, Alexander RW, Townsend CM Jr, Thompson JC. Inhibition of growth of two human pancreatic adenocarcinomas in vivo by somatostatin analog SMS 201–995.Am J Surg 1988; 155: 29–35.

    PubMed  CAS  Google Scholar 

  94. Davies NM, Kapur P, Gillespie J, Schally AV, Guillou PJ, Poston GJ. Inhibitory effect of somatostatin analog RC-160 on EGF-and transforming growth factor alpha (TGF-A)-stimulated pancreatic cancer growth in vivo.Br J Cancer 1991; 64(Suppl 15): 4.

    Google Scholar 

  95. Schally AV, Srkalovic G, Szende B, Redding TW, Janaky T, Juhasz A, et al. Antitumor effects of analogs of LH-RH and somatostatin: experimental and clinical studies.J Steroid Biochem Mol Biol 1990; 37: 1061–1067.

    PubMed  CAS  Google Scholar 

  96. Szende B, Srkalovic G, Schally AV, Lapis K, Groot K. Inhibitory effects of analogs of luteinizing hormone-releasing hormone and somatostatin on pancreatic cancers in hamsters.Cancer 1990; 65: 2279–2290.

    PubMed  CAS  Google Scholar 

  97. Paz-Bouza JR, Redding TW, Schally AV. Treatment of nitrosamine-induced pancreatic tumors in hamsters with analogues of somatostatin and luteinizing hormone-releasing hormone.Proc Natl Acad Sci USA 1987; 84: 1112–1116.

    PubMed  CAS  Google Scholar 

  98. Poston GJ, Gillespie J, Guillou PJ. Biology of pancreatic cancer.Gut 1991; 32: 800–812.

    PubMed  CAS  Google Scholar 

  99. Szende B, Zalatnai A, Schally AV. Programmed cell death (apoptosis) in pancreatic cancer of hamsters after administration of analogs of luteinizing hormone releasing hormone and somatostatin.Proc Natl Acad Sci USA 1989; 86: 1643–1647.

    PubMed  CAS  Google Scholar 

  100. Liebow C, Reilly C, Serrano M, Schally AV. Somatostatin analogues inhibit growth of pancreatic cancer by stimulating tyrosine phosphatase.Proc Natl Acad Sci USA 1989; 86: 2003–2007.

    PubMed  CAS  Google Scholar 

  101. Buscail L, Delesque N, Estere J-P, Saint-Laurent N, Prats H, Clerc P, et al. Stimulation of tyrosine phosphatase and inhibition of cell proliferation by somatostatin analogues: mediation by human somatostatin receptor subtypes SSTR1 and SSTR2.Proc Natl Acad Sci USA 1994; 91: 2315–2319.

    PubMed  CAS  Google Scholar 

  102. Vennin PH, Peyret JP, Bonneterre J. Effect of the long-acting somatostatin analogue SMS 201–995 in advanced breast cancer.Anticancer Res 1989; 9: 153–156.

    PubMed  CAS  Google Scholar 

  103. Guliana JM, Guillausseau PJ, Caron Siame-Mourot C, Calmettes C, Modigliant E. Effects of short-term subcutaneous administration of SMS 201–995 on calcitonin plasma levels in patients suffering from medullary thyroid carcinoma.Horm Metab Res 1989; 21: 584–586.

    PubMed  CAS  Google Scholar 

  104. Kraenzlin ME, Ch’ng JC, Wood SM, Carr DH, Bloom SR. Long-term treatment of a VIPoma with somatostatin analogue resulting in remission of symptoms and possible shrinkage of metastases.Gastroenterology 1985; 88: 185–187.

    PubMed  CAS  Google Scholar 

  105. Parmar H, Bogden A, Mollard M, de Rouge B, Phillips RH, Lightman SL. Somatostatin and somatostatin analogues in oncology.Cancer Treat Rev 1989; 16: 95–115.

    PubMed  CAS  Google Scholar 

  106. Ebert M, Friess H, Beger H, et al. Role of octreotide in the treatment of pancreatic cancer.Digestion 1994; 55(Suppl 1): 48–51.

    PubMed  Google Scholar 

  107. Weckbecker G, Tolcsvai L, Stolz B, Pollak M, Brun C. Somatostatin analogue octreotide enhances the antineoplastic effects of tamoxifen and ovariectomy on 7,12-dimethylbenz(a)anthracene-induced rat mammary carcinomas.Cancer Res 1994; 54: 6334–6337.

    PubMed  CAS  Google Scholar 

  108. Yousefi S, Vaziri N, Carandang G, Le W, Yamamoto R, Granger G, Ocariz J, Cesario T. The paradoxical effects of somatostatin on the bioactivity and production of cytotoxins derived from human peripheral blood mononuclear cells.Br J Cancer 1991; 64: 243–246.

    PubMed  CAS  Google Scholar 

  109. Niedermuhlbichler M, Wiedermann CJ. Suppression of superoxide release from human monocytes by somatostatin-related peptides.Regul Peptides 1992; 41: 39–47.

    CAS  Google Scholar 

  110. Weckbecker G, Raulf F, Tolcsvai L, Bruns C. Potentiation of the anti-proliferative effects of anti-cancer drugs by octreotide in vitro and in vivo.Digestion 1996; 57(Suppl 1): 22–28.

    PubMed  CAS  Google Scholar 

  111. Radulovic S, Nagy A, Szoke B, et al. Cytotoxic analog of somatostatin containing methotrexate inhibits growth of MIA PaCa-2 human pancreatic cancer xenografts in nude mice.Cancer Lett 1992; 62: 263–271.

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Surgery and Medicine, McGill University, Montreal, Canada

    Lawrence Rosenberg

  2. Centre for Pancreatic Diseases, Montreal General Hospital, Montreal, Canada

    Lawrence Rosenberg

Authors
  1. Lawrence Rosenberg
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Rosenberg, L. Treatment of pancreatic cancer. Int J Pancreatol 22, 81–93 (1997). https://doi.org/10.1007/BF02787465

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF02787465

Key Words

Search

Navigation